incrementalepidemiology
Hereditary alpha-tryptasemia identified as common SM confounder
Systemic Mastocytosis →Summary
Lyons et al. (2016) identified hereditary alpha-tryptasemia (HaT), caused by increased TPSAB1 copy number, in 5-6% of the general population. HaT elevates baseline tryptase independent of mast cell burden, complicating SM diagnosis. Updated WHO/ICC criteria now account for HaT when interpreting elevated tryptase in suspected SM cases.
More from Systemic Mastocytosis
significantTreatment update
PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM
significantNew research
Swedish and Danish population-based studies reveal higher SM prevalence than expected
breakthroughTreatment update
Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)
incrementalTreatment update
Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable
ID: systemic-mastocytosis-update-9Type: epidemiologyImpact: incremental